FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912062763> ?p ?o ?g. }

• W2912062763 endingPage "3035" @default.
• W2912062763 startingPage "3035" @default.
• W2912062763 abstract "Abstract Background: While several population-based studies have reported on adverse outcomes and life expectancy in myeloproliferative neoplasms (MPN) (JCO. 2015;33:2288; AJH. 1999;61:10; Leukemia. 2013;27:1874; JCO. 2012;30:2995), large-scale studies reporting mature data have been rare and important questions remain unanswered. The current study documents the Mayo Clinic (MC) decades-long experience with over 3,000 consecutive MPN patients including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) with the majority of patients followed until death. Herein, we provide mature, and importantly, risk-stratified survival data and disease complication estimates. Methods: Study patients were recruited from MC, Rochester, MN, USA between 10/27/1967 and 12/29/2017. All MPN diagnoses and documentation of fibrotic/leukemic transformations were in accordance with the 2016 World Health Organization criteria (Blood. 2016;127:2391). Clinical and laboratory data were abstracted from medical records. Risk-stratification used conventional risk models considering age, leukocytes, and venous thrombosis for PV (Leukemia. 2013;27:1874), international prognostic score for ET (Blood. 2012;120:1197), and dynamic international prognostic scoring system for PMF (Blood. 2010;115:1703). Statistical analyses were based on parameters obtained at the time of referral to MC which, in the majority of cases, coincided with or was within 1 year of diagnosis. All patients were followed from diagnosis until death or date of last follow-up/contact. Recipients of allogeneic stem cell transplants were censored at the time of transplant. Standard statistical methods and time-to-event curves prepared using the Kaplan-Meier method were used to compare MPN subgroups. Survival data for low-risk ET/PV were compared with age- and sex-matched controls from Olmstead County, MN, USA. JMP® Pro 13.0.0 software (SAS Institute, Cary, NC, USA) was used for all analyses. Results: 3,023 consecutive patients (median age 62 years, range 18-96; 51% males) were considered, including 89% diagnosed within the year: 665 PV, 1076 ET and 1282 PMF. Conventional risk stratification in 2925 evaluable patients revealed low, intermediate, and high-risk status in 26%, 29%, and 45% of PV and 30%, 42%, and 28% of ET patients, respectively, while PMF cases were attributed low (14%), intermediate-1 (38%) -2 (40%) and high (8%) risk (Table 1). After a median follow-up of 8.2 years for PV (range 0-39), 9.9 for ET (range 0-47), and 3.2 for PMF (range 0-31), 1631 (54%) deaths, 183 (6%) leukemic transformations, 244 (14%) fibrotic progressions, and 516 (17%) thrombotic events were recorded (Table 1). Median overall survival (OS) was 18 years for ET, 15 for PV and 4.4 for PMF (p<0.05 for all inter-group comparisons) (Figure 1A). Leukemia-free survival was similar for ET and PV (p=0.22) and significantly worse for PMF (p<0.001) (Figure 1B). PV, compared to ET, was associated with higher risk of fibrotic progression (p<0.001) (Figure 1C). Thrombosis risk after diagnosis was highest in PV and lowest in PMF (p=0.002 for PV vs ET; 0.56 for ET vs PMF; and 0.001 for PV vs PMF) (Figure 1D). Following risk stratification, median OS in low-risk ET (28 years) and low-risk PV (27 years) were superimposed (p=0.89) (Figure 2). Similarly, intermediate or high-risk PV and ET patients had comparable OS within each risk strata (p=0.23 and 0.11, respectively). Low-risk PMF survival was analogous to that of intermediate-risk PV (p=0.06). All other risk-stratified categories disclosed significantly different inter- and intra-group survival patterns (p<0.001) (Figure 2). Despite their categorization as favorable-risk disease, both low-risk ET and low-risk PV displayed excess mortality relative to age- and sex-matched controls with median survival of 26.7 and 28.1 years respectively, compared to the expected 37.5 and 39.2 years (p<0.001) (Figure 3). Conclusions: The current study provides large-scale and uniquely mature survival and outcomes data in MPN and highlights MPN subgroup risk categorization as cardinal in appraising disease natural history. Interestingly, OS was only marginally better in ET, compared to PV, while the latter clearly displayed a higher risk of thrombosis and fibrotic progression. Moreover, data disclosed shortened life expectancy relative to matched controls even in MPN with favorable risk attribution. Disclosures Busque: BMS: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; Paladin: Consultancy." @default.
• W2912062763 created "2019-02-21" @default.
• W2912062763 creator A5002643270 @default.
• W2912062763 creator A5006929029 @default.
• W2912062763 creator A5008437556 @default.
• W2912062763 creator A5013866554 @default.
• W2912062763 creator A5014255803 @default.
• W2912062763 creator A5014945673 @default.
• W2912062763 creator A5016216479 @default.
• W2912062763 creator A5024612499 @default.
• W2912062763 creator A5043492753 @default.
• W2912062763 creator A5046100726 @default.
• W2912062763 creator A5061275603 @default.
• W2912062763 creator A5064374340 @default.
• W2912062763 creator A5067675521 @default.
• W2912062763 creator A5072463255 @default.
• W2912062763 creator A5078452873 @default.
• W2912062763 creator A5079007941 @default.
• W2912062763 creator A5079398488 @default.
• W2912062763 creator A5080232575 @default.
• W2912062763 creator A5080965667 @default.
• W2912062763 date "2018-11-29" @default.
• W2912062763 modified "2023-10-01" @default.
• W2912062763 title "3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups" @default.
• W2912062763 doi "https://doi.org/10.1182/blood-2018-99-109740" @default.
• W2912062763 hasPublicationYear "2018" @default.
• W2912062763 type Work @default.
• W2912062763 sameAs 2912062763 @default.
• W2912062763 citedByCount "1" @default.
• W2912062763 countsByYear W29120627632021 @default.
• W2912062763 crossrefType "journal-article" @default.
• W2912062763 hasAuthorship W2912062763A5002643270 @default.
• W2912062763 hasAuthorship W2912062763A5006929029 @default.
• W2912062763 hasAuthorship W2912062763A5008437556 @default.
• W2912062763 hasAuthorship W2912062763A5013866554 @default.
• W2912062763 hasAuthorship W2912062763A5014255803 @default.
• W2912062763 hasAuthorship W2912062763A5014945673 @default.
• W2912062763 hasAuthorship W2912062763A5016216479 @default.
• W2912062763 hasAuthorship W2912062763A5024612499 @default.
• W2912062763 hasAuthorship W2912062763A5043492753 @default.
• W2912062763 hasAuthorship W2912062763A5046100726 @default.
• W2912062763 hasAuthorship W2912062763A5061275603 @default.
• W2912062763 hasAuthorship W2912062763A5064374340 @default.
• W2912062763 hasAuthorship W2912062763A5067675521 @default.
• W2912062763 hasAuthorship W2912062763A5072463255 @default.
• W2912062763 hasAuthorship W2912062763A5078452873 @default.
• W2912062763 hasAuthorship W2912062763A5079007941 @default.
• W2912062763 hasAuthorship W2912062763A5079398488 @default.
• W2912062763 hasAuthorship W2912062763A5080232575 @default.
• W2912062763 hasAuthorship W2912062763A5080965667 @default.
• W2912062763 hasConcept C126322002 @default.
• W2912062763 hasConcept C2778837598 @default.
• W2912062763 hasConcept C2780007613 @default.
• W2912062763 hasConcept C2780076729 @default.
• W2912062763 hasConcept C2780240888 @default.
• W2912062763 hasConcept C2780817109 @default.
• W2912062763 hasConcept C2781057849 @default.
• W2912062763 hasConcept C2908647359 @default.
• W2912062763 hasConcept C71924100 @default.
• W2912062763 hasConcept C99454951 @default.
• W2912062763 hasConceptScore W2912062763C126322002 @default.
• W2912062763 hasConceptScore W2912062763C2778837598 @default.
• W2912062763 hasConceptScore W2912062763C2780007613 @default.
• W2912062763 hasConceptScore W2912062763C2780076729 @default.
• W2912062763 hasConceptScore W2912062763C2780240888 @default.
• W2912062763 hasConceptScore W2912062763C2780817109 @default.
• W2912062763 hasConceptScore W2912062763C2781057849 @default.
• W2912062763 hasConceptScore W2912062763C2908647359 @default.
• W2912062763 hasConceptScore W2912062763C71924100 @default.
• W2912062763 hasConceptScore W2912062763C99454951 @default.
• W2912062763 hasIssue "Supplement 1" @default.
• W2912062763 hasLocation W29120627631 @default.
• W2912062763 hasOpenAccess W2912062763 @default.
• W2912062763 hasPrimaryLocation W29120627631 @default.
• W2912062763 hasRelatedWork W2098715171 @default.
• W2912062763 hasRelatedWork W2466214013 @default.
• W2912062763 hasRelatedWork W2594407038 @default.
• W2912062763 hasRelatedWork W2806912326 @default.
• W2912062763 hasRelatedWork W2903749170 @default.
• W2912062763 hasRelatedWork W2932618166 @default.
• W2912062763 hasRelatedWork W3083720543 @default.
• W2912062763 hasRelatedWork W4310106524 @default.
• W2912062763 hasRelatedWork W4311679846 @default.
• W2912062763 hasRelatedWork W638187407 @default.
• W2912062763 hasVolume "132" @default.
• W2912062763 isParatext "false" @default.
• W2912062763 isRetracted "false" @default.
• W2912062763 magId "2912062763" @default.
• W2912062763 workType "article" @default.